Fore Biotherapeutics recently named Matthew E. Ros as the CEO and director of the board to lead the company's operations in the U.S and Jerusalem.
“After an extensive search, we are delighted and very excited to welcome Matt as our next CEO,” Dieter Weinand, the chairman of the board of directors, said in a press release. “Matt brings enormous experience to grow and scale Fore as an innovative biotech given his track record of success in both mature and emerging life science companies. He is the right leader for our company, and the board and I are delighted to partner with Matt to navigate Fore’s path to continued success."
Ros brings in more than three decades of biotechnology experience, which he garnered at Epizyme, Inc., serving as executive vice president and chief strategy and business officer, according to a press release. He also worked as COO and global head of the Oncology Business Unit at Sanofi-Genzyme, ARIAD Pharmaceuticals, Bristol Myers Squibb. The executive also specializes in developing and leading sales, marketing, franchise strategy and business strategies.
"I am honored and humbled to lead Fore and work alongside the incredibly talented management team to build upon what has been accomplished to date,” Ros said in a press release. “Fore is poised to develop targeted treatments that fundamentally transform the way cancer is treated. The company’s functional genomics platform provides us with the opportunity to serve cancer patients with novel, innovative medicines.”
According to the press release, Fore Biotherapeutics identifies a variety of “mutations across validated oncological targets and in-licenses clinical-stage small molecule assets to develop for hyper-targeted populations” using “an integrated functional genomics and machine learning drug discovery engine.”
The clinical-stage biotechnology company’s goal for the upcoming months is to finalize enrollment of its Phase 1/2a study and to launch a registrational Phase 2 study of its clinical Class I/II BRAF inhibitor, FORE8394.